期刊
GLIA
卷 68, 期 10, 页码 1957-1967出版社
WILEY
DOI: 10.1002/glia.23807
关键词
GPR17; neuroinflammatory diseases; oligodendrocyte progenitors; remyelination; signal transduction
资金
- Fondazione Cariplo [2015-0910]
- Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica [GPR17ALS, GPR17ALS-1]
- Fondazione Italiana Sclerosi Multipla [2017/R/1]
- Ministero dell'Istruzione, dell'Universita e della Ricerca
- Department of Excellence 2018-2022 [2017NSXP8J]
- Universita degli Studi di Milano
Remyelination, namely, the formation of new myelin sheaths around denuded axons, counteracts axonal degeneration and restores neuronal function. Considerable advances have been made in understanding this regenerative process that often fails in diseases like multiple sclerosis, leaving axons demyelinated and vulnerable to damage, thus contributing to disease progression. The identification of the membrane receptor GPR17 on a subset of oligodendrocyte precursor cells (OPCs), which mediate remyelination in the adult central nervous system (CNS), has led to a huge amount of evidence that validated this receptor as a new attractive target for remyelinating therapies. Here, we summarize the role of GPR17 in OPC function, myelination and remyelination, describing its atypical pharmacology, its downstream signaling, and the genetic and epigenetic factors modulating its activity. We also highlight crucial insights into GPR17 pathophysiology coming from the demonstration that oligodendrocyte injury, associated with inflammation in chronic neurodegenerative conditions, is invariably characterized by abnormal and persistent GPR17 upregulation, which, in turn, is accompanied by a block of OPCs at immature premyelinating stages. Finally, we discuss the current literature in light of the potential exploitment of GPR17 as a therapeutic target to promote remyelination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据